TP53 and neoplasm: In HCC, because there is no obvious correlation between TMB and immune infiltration, and the expression of PD-L1 in tumor is low, future research still needs to develop new markers to predict the efficacy of PD-1/PD-L1 inhibitors in HCC, and whether the TP53 mutation can be used as a predictor for the efficacy of immunotherapy in HCC needs further illustrations.